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Abstract
Between-country differences in medical and sociodemographic variables, and patient-related outcomes
(PROs) before treatment might explain published variations of side effects after radical prostatecomy (RP) or
radiotherapy (RAD) for prostate cancer (PCa). This hypothesis was tested among 1908 patients from the United
States, Spain, and Norway. Signiﬁcant between-country differences were observed for most factors investi-
gated before treatment. The observations should be considered in comparison of the frequency and severity of
internationally published studies.
Background: In men with PCa, large variations of PROs after RP or high-dose RAD might be related to between-
country differences of medical and sociodemographic variables, and differences in PROs before treatment in the
sexual and urinary domains. Patients and Methods: In 1908 patients with localized PCa from Norway, the United
States, or Spain, the relation between medical (prostate-speciﬁc antigen, Gleason score, cT-category) and socio-
demographic variables (age, education, marital status) before treatment was investigated. Using the Expanded
Prostate Cancer Index Composite questionnaire, PROs before treatment within the sexual and urinary domains were
also considered. Results: Compared with the European patients, American patients were younger, fewer had co-
morbid conditions, and more had a high education level. Fifty-three percent of the US men eligible for RP had low-risk
tumors compared with 42% and 31% among the Norwegian and the Spanish patients, respectively. Among the
Spanish RAD patients, 54% had had low-risk tumors compared with 34% of the American and 21% of the Norwegian
men planned for RAD, respectively. Compared with the European patients, signiﬁcantly fewer US patients reported
moderate or severe sexual dysfunction and related problems. In most subgroups, the number of patients with sexual
or urinary dysfunction exceeded that of patients with bother related to the reported dysfunction. Conclusion: Sta-
tistically signiﬁcant between-country differences were observed in medical and sociodemographic variables, and in
PROs before treatment within the sexual and urinary domains. Large differences between reported dysfunction and
related problems within the sexual and urinary domains indicate that dysfunction and bother should be reported
separately in addition to calculation of summary scores. The documented differences, not at least regarding PROs,
might in part explain the large variation of side effects after treatment evident in the medical literature.
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Between-Country Differences Before Treatment in PCa
2 - CliIntroduction  Known level of prostate-speciﬁc antigen (PSA) and Gleason score
Standard curative treatment of prostate cancer (PCa) patients com-
prises radical prostatectomy (RP) and high-dose radiotherapy (RAD)
with or without adjuvant androgen deprivation therapy (ADT). After
adjustment for risk group allocation, PCa-speciﬁc survival appears to
be similar after both treatment modalities.1-3 However, the patterns of
“typical adverse effects (AEs)” (dysfunction within the urinary, sexual,
bowel, and hormonal domains and related problems) differ substan-
tially.4,5 Further, even though comparisons are restricted either to RP or
RAD, large and generally unexplained variations of the frequency and
severity of typical AEs are reported across studies and countries.6-10
Such differences in patient-related outcomes (PROs) after treatment
might affect the individual patient’s choice of RP versus RAD.
Except for different treatment techniques, variations of AEs after
treatment might be related to differences in medical factors before
treatment (tumor risk group allocation, comorbidity, general health
condition) and sociodemographic factors (age, educational level,
civil status). Some groups have documented some effect of PROs
before treatment on AEs after RP or RAD.11,12 However, the
knowledge on between-country differences of PROs within the
urinary and sexual domain is limited. Only Namiki et al have re-
ported on differences of sexual function and bother in Japanese and
American men before treatment.13
Our group has initiated a cohort study with research groups in the
United States and Spain to perform between-country comparisons
of variables before and after treatment and patient-reported typical
AEs among patients treated with curative RP or RAD for PCa. The
present article describes for each country, and separately for RP and
RAD, medical and sociodemographic factors before treatment and
PROs within the sexual, urinary, bowel, and hormonal domains.
We also evaluated the correlation between patient-reported dys-
function and related problems. Finally, for each country we assessed
the associations between factors before treatment and RP or RAD.
We anticipated considerable between-country differences in the
distribution of variables before treatment and the strength of their
associations with the selected treatment. We also expected between-
country differences in patient-reported treatment dysfunction and
problems before treatment within the sexual and urinary domains.
Patients and Methods
Study Design and Study Sites
This study represents a collaboration between Oslo University
Hospital, Norway, the PROSTAQA (PRostate Cancer Outcomes and
Satisfaction with Treatment Quality Assesment) Study Group in
Boston, MA, and The Spanish Group of Localized Prostate Cancer,
Barcelona, Spain. Each group has published results regarding PROs
before and after RP and RAD.14-18 However, because the present study
only included patients with clinically categorized T1 or T2 tumors, 28
RP and 80 RAD patients with T3/T4 tumors were excluded from the
original Norwegian sample. In the Spanish sample, 10 RP and 65 RAD
patients were excluded because of hormonal treatment before inclusion.
Patient Sampling
Eligible patients for the present study fulﬁlled the following criteria:
 Histologically conﬁrmed PCa
 Clinical stage T1 or T2 tumornical Genitourinary Cancer Month 2014before treatment
 Planned RP or RAD
 No ADT before completion of the questionnaire before
treatmentTreatment Techniques
Radical prostatecomy was performed using retropubic, laparo-
scopic, or robot-assisted techniques with or without nerve-sparing
procedures. RAD (65 Gy) was delivered as intensity modulated
RAD, 3-D conformal technique, or a combination of high-dose
brachytherapy and external beam RAD. Patients receiving low-
dose brachytherapy alone were excluded because this option was
not available in Norway.19
Clinical Variables
Risk Groups. Three risk groups were deﬁned; low-risk: cT1-T2a
and Gleason score 6 and PSA < 10 ng/mL; intermediate-risk:
cT2b-T2c or Gleason score 7 or PSA 10-20 ng/mL; and high-
risk: Gleason score 8-10 and/or PSA > 20 ng/mL.20
Other Variables Assessed Before Treatment according to Patient
Reports. The level of education separated “less than high school”
from “high school or more.” “Single” versus “paired relation”
described the relationship status. Comorbidity was deﬁned as the
presence of at least 1 of 5 adverse health conditions: (1) diabetes; (2)
heart failure and/or myocardial infarction and/or angina; (3) stroke;
(4) ulcus and/or irritable bowel disease; and (5) asthma and/or
bronchitis and/or breathing problems.
Expanded PCa Index Composite. Before treatment the patients
completed a questionnaire containing a version of the Expanded
Prostate Cancer Index Composite (EPIC) instrument. EPIC assesses
patient-reported sexual, urinary, and bowel dysfunction and prob-
lems (“bother”)21 and hormone treatment-related AEs.21,22 The
original questionnaire includes 50 items (EPIC-50) but was later
abbreviated to 26 items (EPIC-26).22 All questions in EPIC-26,
completed by the American patients, are included in EPIC-50,
used by the Norwegian and Spanish men. The present report is
based on responses to items in EPIC-26.
Using 4- or 5-point Likert scales, the patient scored his function
and related problems within each of the 4 domains (sexual, urinary,
bowel and hormonal). The individual scores were then transformed
into scales ranging from 0 to 100, with 0 representing maximum
dysfunction/maximum problem and 100 indicating no dysfunction/
no problem.23 The scores within each domain were ﬁnally averaged.
The resulting summary scores reﬂect functional aspects and prob-
lem experience within the sexual, urinary irritation/obstruction,
urinary incontinence, bowel, or hormonal domains. Our patients’
answers to each of the 26 EPIC items were also dichotomized ac-
cording to Sanda et al,16 enabling separation patients with no/very
small/small dysfunctions/problems (“absent dysfunction/problems”)
from those with moderate/big dysfunctions/problems (“present
dysfunction/problems”). In addition, we calculated mean scores for
items which content addressed dysfunction as opposed to problem
experience.
Table 1 Demographic and Disease Characteristics of the Patients Before Treatment
Variable
Radical Prostatectomy Radiotherapy
Norway
(n [ 627)
USA
(n [ 603)
Spain
(n [ 123) P
Total
(n [ 1353)
Norway
(n [ 126)
USA
(n [ 293)
Spain
(n [ 126) P
Total
(n [ 555)
Age, Median (Range);
< 65 Years
64 (44-78);
382 (61)
60 (39-80);
460 (76)
65 (45-75);
64 (52)
<.001a,b;
<.001a,b
62 (39-80);
906 (67)
67 (51-78);
41 (33)
69 (46-85);
86 (29)
70 (55-83);
25 (19)
.008a,c;
.009c
69 (46-85);
152 (27)
No Comorbid Condition 450 (72) 513 (85) 77 (63) <.001a,b 1040 (77) 64 (51) 200 (67) 77 (57) <.001a 341 (62)
Paired Relationship 584 (93) 523 (87) 109 (87) <.001a 1216 (90) 102 (83) 227 (78) 118 (87) .018b 447 (81)
Education Greater Than
High School Level
322 (52) 511 (85) 8 (7) <.001a,b,c 841 (62) 57 (46) 211 (72) 16 (12) <.001a,b,c 284 (52)
PSA, ng/mL
Median (Range) 8.2 (1.6-75) 5.5 (0.5-72) 7.4 (4-23) .002a,b,c 6.9 (0.5-75) 9.8 (3-87) 6.3 (0.5-99) 7.6 (1.2-38) .009a,b,c 7.6 (0.5-99)
PSA Group <.001a <.001a,c
10.0 434 (69) 525 (87) 99 (81) 1058 (78) 66 (52) 226 (77) 114 (84) 406 (73)
>10-20 162 (26) 65 (11) 45 (15) 250 (18) 38 (30) 45 (15) 15 (11) 98 (18)
>20 31 (5) 13 (2) 1 (1) 45 (3) 22 (18) 22 (8) 7 (5) 51 (9)
cT Category <.001a .005a,c
T1 393 (63) 437 (73) 82 (67) 912 (67) 53 (42) 203 (69) 82 (67) 353 (60)
T2a 142 (23) 130 (22) 33 (27) 305 (23) 39.0 (31) 56 (19) 33 (27) 133 (24)
T2b 53 (9) 23 (4) 8 (7) 84 (6) 15 (12) 24 (8) 8 (7) 56 (10)
T2c 39 (6) 13 (2) 0 (0) 52 (4) 18 (14) 10 (3) 0 (0) 32 (6)
Gleason Score .01a,c <.001b,c
6 290 (46) 370 (61) 71 (58) 731 (54) 42 (34) 130 (44) 99 (73) 271 (50)
7 280 (45) 207 (34) 48 (39) 535 (40) 61 (49) 122 (42) 32 (24) 215 (39)
8 57 (9) 26 (4) 3 (3) 86 (6) 22 (18) 42 (14) 3 (8) 67 (12)
Risk Group .01a,b,c <.001a,c
Low 191 (31) 322 (53) 51 (42) 564 (42) 26 (21) 100 (34) 73 (54) 199 (36)
Intermediate 354 (57) 246 (41) 68 (55) 668 (49) 65 (52) 139 (47) 52 (38) 256 (46)
High 82 (13) 35 (6) 4 (3) 121 (9) 35 (28) 54 (18) 11 (8) 100 (18)
Data are presented as n (%).
Abbreviations: PSA ¼ prostate-speciﬁc antigen; USA ¼ United States of America.
aNorway versus United States.
bUSA versus Spain.
cNorway versus Spain.
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Between-Country Differences Before Treatment in PCa
4 - CliData Management and Statistics
After approval by the local ethical committees, a combined
project data ﬁle was established, which for each patient contained
medical and sociodemographic data (treatment type, risk group, age,
education) and EPIC-assessed PROs. The current study investigated
only variables before treatment.
Using PASW for PC version 18.0 and separately for the RP and
RAD groups, variables were described with means and standard
deviations or as proportions. Between-country differences were
analyzed using 1-way analysis of variance for continuous variables.
Crude associations between pairs of categorical variables were
assessed using c2 tests.
Separately for each country, associations between type of treatment
(RAD or RP with RP given as a reference) were assessed using uni-
variate and multiple logistic regressions. The strength of associations
was expressed according to odds ratios (ORs) and 95% conﬁdence
intervals. P-values <.01 were considered statistically signiﬁcant.
Results
A total of 1908 patients (1353 planned for RP; 555 planned for
RAD) were eligible for the study based on their status before
treatment. There were 753 men from Norway (RP: n ¼ 627; RAD:
n ¼ 126), 896 from the United States (RP: n ¼ 603; RAD: n ¼
293), and 249 from Spain (RP: n ¼ 123; RAD: n ¼ 126). The
majority of patients from all three countries were caucasian.
Sociodemographic and Medical Variables
Radical Prostatecomy Patients. In the RP group, signiﬁcantly more
American patients were younger than 65 years old (76%) compared
with those from Norway (61%) or Spain (52%) (Table 1). Further,
among the US patients we also observed the highest prevalence
of men without comorbidities and the highest proportion of pa-
tients with at least a high school education. More than half of the
American men who received surgery had low-risk tumors compared
with 31% and 42% of the Norwegian and Spanish men, respec-
tively. In the Norwegian RP group, signiﬁcantly more patients hadTable 2 Mean EPIC Sum Scores for the 4 Domains for Each Treatm
Variable (a)
Radical Prostatectom
Norway USA Spain
Urinary
Incontinence score (1, 2, 3, 4a) 94 (12) 94 (13) 94 (15) .99
Irritative/obstructive score (4b, c, d, e) 83 (15) 87 (15) 94 (12) <.00
Overall problem (5) 75 (28) 80 (27) 87 (28) .01
Sexual
Sexual score (8a, b, 9, 10, 11, 12) 67 (25) 78 (23) 62 (25) <.00
Bowel
Bowel score (6a-e, 7) 95 (9) 97 (8) 99 (3) .00
Hormonal
Hormonal score (13a-e) 91 (11) 92 (11) 96 (10) <.00
Data are presented as mean (SD).
Abbreviations: EPIC ¼ Expanded Prostate Cancer Index Composite; USA ¼ United States of Americ
aEPIC questions used to calculate the mean score.
bUSA versus Spain.
cNorway versus USA.
dNorway versus Spain.
nical Genitourinary Cancer Month 2014high-risk disease (13%) compared with the US (6%) and Spanish
(3%) groups.
Radiotherapy Patients. Within the RAD group, more Norwegian
patients were younger than 65 years old compared with the Spanish
patients (Table 1). Among the American patients, 72% had
completed high school, the comparable proportions being 46% and
12% in the Norwegian and Spanish groups, respectively. More than
half of the Spanish patients in the RAD group (54%) had low-risk
tumors compared with 21% in the Norwegian and 34% in the US
groups. The highest proportion of patients with high-risk tumors
was observed in the Norwegian patients (28%).
Responses to the EPIC-26
Urinary Domain. Independent of country and treatment type,
mean scores before treatment were generally high within the urinary
domain; the mean urinary incontinence score being >90 for all
groups, corresponding to >98% of the patients not using pads
(Tables 2 and 3). Thus, summary scores principally reﬂected the
irritative/obstructive urinary dysfunction/bother, with signiﬁcant
between-country differences. Further, only about half of Norwegian
and US patients in respectively the RP and RAD group who re-
ported moderate or big dysfunction within the urinary domain also
reported problems (Fig. 1). Among the Spanish patients, the pro-
portion of men with obstructive/irritative symptoms and those
reporting related problems were more similar.
Sexual Domain. In the RP and the RAD groups the lowest mean
scores and the highest percentage of patients with moderate/big
dysfunction were observed within the sexual domain, with the
highest mean scores among the American patients (Tables 2 and 3).
Accordingly, the percentages of patients reporting sexual problems
were lowest among the US men (RP: 12%; RAD: 18%), and
highest among the Spanish men (RP: 28%; RAD: 28%).
In the RAD group approximately half of the patients who
reported sexual dysfunction also experienced sexual problems withent Group in Norway, USA, Spain, and Total Before Treatment
y Radiotherapy
P Total Norway USA Spain P Total
94 (13) 93 (11) 92 (14) 96 (11) .013b 93 (13)
1b,c,d 86 (15) 83 (15) 87 (14) 96 (10) <.001b,d 88 (14)
3b,d 78 (28) 75 (26) 78 (26) 93 (21) <.001b,d 81 (26)
1b,c 72 (25) 50 (27) 59 (29) 57 (27) .01c 57 (28)
2b,c,d 96 (8) 94 (10) 95 (10) 99 (6) <.001b,d 96 (9)
1b,d 92 (11) 88 (13) 92 (12) 96 (11) .001b,d 92 (12)
a.
Table 3 Percent of Patients Reporting Speciﬁc Levels of Distress or Dysfunction for Each Question in EPIC-26a
Variable (b)
Radical Prostatectomy Radiotherapy
Norway
(n [ 627)
USA
(n [ 603)
Spain
(n [ 123) P
Total
(n [ 1353)
Norway
(n [ 126)
USA
(n [ 293)
Spain
(n [ 126) P
Total
(n [ 555)
Urinary Domain
Incontinence
Leaking >1 time per day (1) 3 4 6 .25 4 2 6 1 .04 4
Frequent dribbling (2) <1 2 3 .06 2 <1 2 <1 .32 2
Any pad use (3) 2 1 <1 .66 1 0 <1 <1 .64 <1
Leaking problem (4a)c 2 2 4 .23 2 <1 2 4 .22 2
Irritation or obstructionc
Dysuria (4b) 1 1 2 .28 1 2 1 2 .61 1
Hematuria (4c) 0 <1 <1 .18 <1 0 1 0 .26 <1
Weak stream (4d) 16 12 7 .006d 13 15 13 5 .005d,e 12
Frequency (4e) 20 17 11 .01d 18 21 15 2 <.001d,e 14
Overall urinary problem (5)c 13 11 13 .59 12 11 11 6 .21 10
Sexual Domain
Poor erection (8a) 24 14 23 <.001f 20 46 37 27 .003d 37
Difﬁculty with orgasm (8b) 17 12 15 .071 15 39 32 26 .08 32
Erection not ﬁrm for intercourse (9)g 27 17 43 <.001d,e,f 24 57 48 52 .263 49
Erection not reliable (10)h 27 20 42 .004d,e,f 25 52 44 45 .10 46
Poor sexual function (11)c 32 13 36 <.001e,f 24 56 34 48 .006e,f 43
Overall sexual problem (12)c 18 12 28 .004e,f 17 27 18 28 .01e 24
Abbreviations: EPIC ¼ Expanded Prostate Cancer Index Composite; USA ¼ United States of America.
aThe percent of survey respondents reporting the indicated level of dysfunction in the 3 countries in each treatment group and in total in each treatment group.
bThe number of the EPIC question used.
cModerate or big problem.
dNorway versus Spain.
eUSA versus Spain.
fNorway versus USA.
gErection not ﬁrm included all answers except “ﬁrm enough for intercourse.”
hErection approximately half of the time or less was categorized as “erection not reliable.”
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Figure 1 Percent of Patients Reporting Moderate or Big Problem With Frequency And/Or Weak Stream and Overall Urinary Function
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6 - Clisimilar patterns across the 3 countries (Fig. 2). In the RP group only
for the Spanish and the Norwegian patients, larger differences were
observed between sexually dysfunctioning men and those reporting
related problems. Almost all of the relatively few US patients with
sexual dysfunction also reported sexual problems.
Bowel and Hormonal Domains. High summary scores in the
bowel and hormonal domains were paralleled by low proportions
of men reporting problems in these domains (Table 2). Further
analyses of these minimally affected domains before treatment
were therefore not pursued.Figure 2 Percent of Patients Reporting Poor or Very Poor Ability to
Moderate or Big Problems in the Sexual Domain
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In each of the 3 countries, age 65 years or older was signiﬁcantly
associated with being planned for RAD with considerable numerical
differences as to the respective ORs (Table 4): Norwegian patients
aged 65 years or older were 2.7 times more likely to be planned for
RAD than for RP, whereas the comparable likelihood was reﬂected
by an OR of 7 among US men and 4.5 among Spanish patients.
Among the American and Norwegian patients, but not among the
patients from Spain, comorbidity and presenting with a high-risk
tumor were independently associated with RAD. US patients with
less than a high school education were twice as likely to receive RADFunction Sexually and Percentage of Patients Reporting Overall
SA Spain Total
YPAREHTOIDA
Frequency and/or weak stream (%)
Overall urinary problem (%)
Table 4 Uni- and Multivariate Regression Analysis With RAD the Dependent Variable and RP the Reference
Variable
Norway USA Spain
Univariate
Analysis
Multivariate
Analysis
Univariate
Analysis
Multivariate
Analysis
Univariate
Analysis
Multivariate
Analysis
Marital Status
Living together 1.0 e 1.0 e 1.0 e
Not living together 2.9 (1.7-5.2)a 2.7 (1.4-5.0)b 1.9 (1.3-2.7)a 2.4 (1.5-3.7)a 1.1 (0.6-2.2)c e
Comorbidity
No comorbid condition 1.0 e 1.0 e 1.0 e
One or more comorbid condition 2.5 (1.7-3.7)a 2.1 (1.4-3.2)a 2.6 (1.9-3.7)a 1.7 (1.2-2.6)b 1.4 (0.9-2.3)c e
Age
<65 years 1.0 e 1.0 e 1.0 e
65 years 3.2 (2.1-4.9)a 2.7 (1.7-4.1)a 7.7 (5.7-10.6)a 7.0 (5.0-10.0)a 4.5 (2.8-7.4)a 4.8 (2.9-8.2)a
Education
High school 1.0 e 1.0 e 1.0 e
<High school 1.3 (0.9-1.8)c e 2.2 (1.5-3.0)a 1.9 (1.2-2.9)b 0.5 (0.2-1.2)c e
Risk group
Low 1.0 e 1.0 e 1.0 e
Intermediate 1.3 (0.8-2.2)c 1.1 (0.7-2.0)c 1.8 (1.3-2.5)a 1.5 (1.0-2.1)b 0.7 (0.4-1.1)c e
High 3.1 (1.8-5.5)a 2.9 (1.6-5.4)a 5.0 (3.1-8.0)a 3.4 (1.9-6.1)a 4.2 (1.4-12.9)b 6.9 (2.1-22.2)a
EPIC
Sexual function (question 11)
Small or less problem 1.0 e 1.0 e 1.0 e
Moderate or big problem 2.6 (1.8-3.9)a 1.8 (1.0-2.9)b 3.6 (2.5-5.0)a 1.9 (1.2-2.9)b 2.2 (1.4-3.4)a 2.0 (1.2-3.3)b
Sexual problem (question 12)
Small or less problem 1.0 e 1.0 e 1.0 e
Moderate or big problem 1.7 (1.0-2.6)b 0.9 (0.5-1.6)c 1.6 (1.1-2.4)b 1.1 (0.7-1.7)c 1.3 (0.8-2.1)c —
Data are presented as OR (95% CI).
Abbreviations: EPIC ¼ Expanded Prostate Cancer Index Composite; RAD ¼ radiotherapy; RP ¼ radical prostatecomy; USA ¼ United States of America.
aP  .001.
bP > .001  .05.
cP > .05.
Anne Holck Storås et alcompared with those with higher education levels, with no such
association among the Norwegian and Spanish patients. Sexual
dysfunction before treatment doubled the likelihood of Norwegian
and US patients to receive RAD.
Discussion
Conﬁrming our hypothesis, signiﬁcant between-country differ-
ences emerged for variables before treatment among Norwegian,
American, and Spanish patients planned for either RP or RAD, with
the sociodemographic and medical variables differing more in the
RP than in the RAD group. American men planned for RP were
younger than the European patients. They had comorbidity less
often and more patients had a high education level. Fewer US pa-
tients than patients from the 2 European countries had an aggressive
PCa and fewer of the American men reported sexual dysfunction.
Age 65 years or older increased the likelihood to receive RAD for
patients from all 3 countries although with considerable between-
country variation on the strength of the associations. The propor-
tion of patients with obstructive/irritative urinary dysfunction or
impaired sexual function exceeded the percentage of men who
experienced problems related to their dysfunction for most patients
with between-country differences.Differences in medical characteristics before treatment (tumor
risk group, comorbidity) between patients planned for RP and RAD
are well-known from previous studies.4,24 However, few studies
have dealt in depth with between-country variability of the distri-
bution of these parameters before treatment within either the RP or
RAD group and of the strength of the association with the ﬁnal
treatment. For each treatment modality (RP or RAD), we observed
substantial between-country differences regarding sociodemographic
status, disease characteristics, and dysfunctions before treatment
within the urinary and sexual domains. Our observations thus add
to the results of the study of Namiki et al, which showed that the
American patients were younger, healthier, and had less disease
burden than men from Japan.25 We also showed considerable
between-country differences of the associations between the elected
treatment modality and the medical and sociodemographic vari-
ables. Whether these latter observations reﬂect different views of the
responsible doctors or mirror variability of patient preferences
cannot be decided based on our data. However, the international
literature on typical AEs after treatment has so far considered these
before-treatment between-country differences to a limited extent, as
a possible explanation for the considerable variations in typical AEs
after either RP or RAD reported in the medical literature.Clinical Genitourinary Cancer Month 2014 - 7
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8 - CliAssessment of the patient’s typical AEs after curative treatment
of PCa usually relies on PROs assessed using questionnaires which
often combine dysfunctions and problems as summary scores,
which might unjustiﬁably disregard important differences between
dysfunction and bother. In agreement with Gore et al26 and Reeve
et al,27 our data thus indicate that dysfunction should be separated
from problem evaluation, in addition to reporting summary scores:
within the urinary domain the proportions of US and Norwegian
patients with bother was less than the percentage of men reporting
dysfunction. They were apparently less bothered than indicated by
their impaired function. We do not have data to explain why many
Norwegian and US patients did not regard their impaired urinary
function as a problem. Increased voiding frequency and weak stream
might, however, considered as normality among men in that age
group. In contrast, the number of men reporting dysfunction and
problems was approximately equal among the Spanish patients.
They also represented the group with the least urinary dysfunction
(urinary frequency or weak stream). We speculated whether elderly
Spanish men, more often than the American or Norwegian ones,
view impaired voiding as “normal” and therefore report only the
most disturbing experiences. Also, in the sexual domain, the pro-
portion of patients with dysfunction exceeded those being bothered,
except for the US men who were planned for RP. Many older PCa
patients probably accept impaired sexual function as a common
consequence of aging and comorbidity. In contrast, among the
younger and healthier US patients in the RP group, impaired sexual
function was more often reported as a bothersome loss.
In the multivariate analyses, and similar for the US and Nor-
wegian patients, we observed that erectile dysfunction before
treatment doubled the likelihood to receive RAD. We have no good
explanation for this ﬁnding and tend to view this observation as a
“ﬁnding by chance.”
Our ﬁndings of the between-country differences of the mean
scores of self-reported sexual and erectile function and overall sexual
problems within the RP and RAD groups are new. We speculate
whether such between-country differences, at least in part can
explain the variability of erectile dysfunction after treatment as re-
ported in review articles including studies from multiple countries.9
Several previous analyses have documented that good erectile and
urinary function before treatment predicts a satisfactory outcome
within these domains after treatment, together with young age.11,12,28
Planned analyses of our patients’ PROs after treatment will address
these issues.
Strengths and Limitations
Selection bias can not be overlooked in our study: RP was
planned in more than half of our patients, in particular, in those
from the American and Norwegian cohorts. This observation re-
quires an explanation: for patients with T1 or T2 tumors, the most
common treatment in America and in Norway is RP, especially in
the younger ones.29,30 However, this tendency was not observed in
the Spanish cohort. Most probably the country-related differences
in our study as to RP versus RAD mirror different treatment stra-
tegies and different patient views. Second, well-educated, sexually
active American men might have selected recognized institutions for
their treatment, whereas the Spanish and Norwegian men probably
had this opportunity to a lesser degree and were probably morenical Genitourinary Cancer Month 2014likely to represent the average patient with localized PCa diagnosed
in the respective country. Third, our study covers the past decade,
when also other treatment modalities were available such as low-
dose RAD or active surveillance. For our patients, we lack
detailed information on all selection criteria for the choice of RP or
RAD. We also do not know the degree to which the ﬁnal treatment
election was based on the patient’s or doctor’s preferences, or
whether the patients had been informed about the different treat-
ment options and their AEs. In this mainly descriptive study we
have therefore refrained from discussing the analyzed variables as
selection criteria. Sufﬁcient information on the use of erectile aids
before treatment, important for evaluation of erectile function, was
not available. Finally, the limited number of non-Caucasian patients
prevented analysis of our data stratiﬁed for race.
The main strengths of our study are the large sample size and the
use of the same questions to evaluate function and problems within
the domains expected to be affected by curative treatment of PCa.
The fact all patients were hormone-naive before questionnaire
completion is regarded as an advantage.
Conclusion
In PCa patients from Norway, the United States, or Spain who
were planned to receive RP or RAD, considerable between-country
differences were conﬁrmed before treatment regarding age and risk
group.
Clinical Practice Points
 Our results as to considerable between-group differences of dys-
function and bother within the sexual and urinary domain are new.
 Because factors before treatment might be related to outcomes
after treatment, they should not be overlooked regarding pub-
lished differences of outcomes across countries.
 The ﬁnding of considerable discrepancies between dysfunction
and problem experience within the urinary and sexual domain is a
new observation and should be taken into account in counseling a
patient with PCa before ﬁnal choice of treatment modality.Acknowledgments
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